Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and ARI With or Without 225Ac-J591 for Progressive mCRPC
NCT04946370Phase 2Recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Aug 2021
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of CONV01-α in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Weill Cornell Medicine. Started Aug 2021; status: recruiting.
02
Drugs
CONV01-α
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04946370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04946370.